Disease · EFO_1000178

Chronic Eosinophilic Leukemia, Not Otherwise Specified

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Chronic Eosinophilic Leukemia, Not Otherwise Specified. Diseases, record EFO_1000178. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1000178

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Chronic Eosinophilic Leukemia, Not Otherwise Specified; Open Targets
Open Targets ID: EFO_1000178; Open Targets
Other names: CEL, CEL/hypereosinophilic syndrome, chronic eosinophilic leukemia, chronic eosinophilic leukemia/hypereosinophilic syndrome, eosinophilic leukemia; Open Targets
NCI Thesaurus: C4563; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 7 of its 8 drugs, from ClinicalTrials.gov; Open Targets

Drugs8

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IMATINIB	CHEMBL941	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MELPHALAN	CHEMBL852	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
MESNA	CHEMBL975	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
THIOTEPA	CHEMBL671	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NILOTINIB	CHEMBL255863	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets5

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ABL1	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	2	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
MS4A1	B-lymphocyte antigen CD20	1	B-lymphocyte antigen CD20 binding agent	Phase 2	https://conductscience.org/library/genes/931	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor beta	1	Platelet-derived growth factor receptor beta inhibitor	Phase 2	https://conductscience.org/library/genes/5159	Drugs and targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00109707	A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies	Phase 1/2	507	2021-06-29	Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis	NILOTINIB	Its record names the disease	ClinicalTrials.gov
NCT00067002	Randomized Double Cord Blood Transplant Study	Phase 2	110	2019-05-01	Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic, Lymphoma, Non-Hodgkin	CYCLOPHOSPHAMIDE, FLUDARABINE, MELPHALAN, MESNA, RITUXIMAB, THIOTEPA	Its record names the disease	ClinicalTrials.gov
NCT00276926	Study of STI571 in the Treatment of Patients With Idiopathic Hypereosinophilic Syndrome (HES) and Eosinophilic Leukemias	Phase 2			Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia (CEL), Myeloproliferative Disorders	IMATINIB	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials4

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
CML-CP With Prior Imatinib Only vs CML-AP With Prior Imatinib Only: Participants With (MMR) Major Molecular Response (Phase II)	106 of 299	18 of 122	421	NCT00109707	Trial comparisons
Un-Manipulated CB Arm vs Expanded CB Arm: Number of Participants With Engraftment	45 of 52	44 of 53	105	NCT00067002	Trial comparisons
Un-Manipulated CB Arm vs Expanded CB Arm: serious adverse events	9 of 52	4 of 53	105	NCT00067002	Trial comparisons
Un-Manipulated CB Arm vs Expanded CB Arm: Rate of Acute Graft Versus Host Disease (GVHD)	29 of 45	24 of 44	89	NCT00067002	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26002753	DERIVED	1	PubMed
24057647	DERIVED	1	PubMed
23547655	DERIVED	1	PubMed
21098399	DERIVED	1	PubMed
17715389	DERIVED	1	PubMed
16775235	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_1000178

GET https://conductscience.org/api/diseases/v1/EFO_1000178/drugs

API reference For AI assistants